Talon Therapeutics, Inc. (TLON)
-OTC BB 0.42 
0.04(8.79%) May 17, 3:22PM EDT
| Prev Close: | 0.46 |
|---|
| Open: | 0.45 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.7 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.42 - 0.45 |
|---|
| 52wk Range: | 0.40 - 1.83 |
|---|
| Volume: | 10,350 |
|---|
| Avg Vol (3m): | 37,294 |
|---|
| Market Cap: | 9.13M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.96 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Talon Therapeutics, Inc. Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, May 15)
- TALON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- TALON THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Sat, Apr 6)
- Biotechs With Staggering Potential: Grant Zengat Seeking Alpha(Fri, Apr 5)
- Talon Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Mon, Apr 1)
- Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial ResultsGlobeNewswire(Mon, Apr 1)
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Mon, Apr 1)
- Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results and Business Update on April 1, 2013GlobeNewswire(Tue, Mar 19)
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhiEDGAR Online(Fri, Jan 25)
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Fri, Jan 11)
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jan 7)
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhiEDGAR Online(Fri, Jan 4)
- Ariad Sinks on Safety Warnings With U.S. Drug Approvalat Bloomberg(Fri, Dec 14)
- Tekmira Could Offer Stockholders Huge Rewardsat Seeking Alpha(Thu, Nov 15)
- Talon Therapeutics' CEO Discusses Q3 2012 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Nov 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Talon Therapeutics, Inc., a biopharmaceutical company, develops and commercializes new and differentiated cancer therapies. Its lead product includes Marqibo (vincristine sulfate liposome injection), which is a novel sphingomyelin/cholesterol lipo...
View More